(NASDAQ: CTKB) Cytek Biosciences's forecast annual revenue growth rate of 6.84% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Cytek Biosciences's revenue in 2026 is $204,171,000.On average, 6 Wall Street analysts forecast CTKB's revenue for 2026 to be $27,499,622,476, with the lowest CTKB revenue forecast at $26,298,596,417, and the highest CTKB revenue forecast at $28,438,489,083. On average, 6 Wall Street analysts forecast CTKB's revenue for 2027 to be $29,332,155,785, with the lowest CTKB revenue forecast at $27,286,537,207, and the highest CTKB revenue forecast at $30,618,415,952.
In 2028, CTKB is forecast to generate $32,352,800,895 in revenue, with the lowest revenue forecast at $30,889,615,385 and the highest revenue forecast at $33,561,575,510.